Investigating antigens for vaccines against Valley Fever

Early in vivo expressed antigens and their role in virulence, immune response, and vaccines for coccidioidomycosis

NIH-funded research Northern Arizona University · NIH-10899660

This study is looking into how certain proteins related to Valley Fever can help create a safe and effective vaccine, using animal tests to see how well these new vaccines can boost the immune system, which could eventually protect people from this growing disease.

Quick facts

Grant typeNIH-funded research
Study typeNIH-funded research
Funding institutionNorthern Arizona University NIH-funded
Lab location1 site (Flagstaff, United States)
Project IDNIH-10899660 on NIH RePORTER

What this research studies

This research focuses on understanding the role of early expressed antigens in the disease coccidioidomycosis, commonly known as Valley Fever. It aims to develop a safe and effective vaccine by exploring nucleic acid vaccines, such as DNA and RNA, which can induce strong immune responses without the risks associated with live infections. The study will utilize animal models to assess the immune response and virulence of these antigens, providing insights that could lead to a viable vaccine for humans. Patients may benefit from advancements in vaccine development that could protect against this increasingly prevalent disease.

Who could benefit from this research

Good fit: Ideal candidates for participation or benefit from this research include individuals living in arid regions who are at risk for Valley Fever.

Not a fit: Patients who do not reside in areas where Valley Fever is prevalent may not receive benefit from this research.

Why it matters

Potential benefit: If successful, this research could lead to the development of a safe and effective vaccine for Valley Fever, significantly reducing the incidence of the disease.

How similar studies have performed: Previous research has shown promise in using nucleic acid vaccines for other diseases, indicating potential success for this novel approach in developing a vaccine for Valley Fever.

Where this research is happening

Flagstaff, United States

Researchers

About this research

  1. This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
  2. Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
  3. For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Last reviewed 2026-06-13 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.